{"id":"NCT00413699","sponsor":"Pfizer","briefTitle":"Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis","officialTitle":"A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02-05","primaryCompletion":"2016-11-30","completion":"2017-10-26","firstPosted":"2006-12-20","resultsPosted":"2018-03-27","lastUpdate":"2018-10-30"},"enrollment":4488,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]}],"arms":[{"label":"Open-Label Active Treatment Enrolled from Phase 2","type":"EXPERIMENTAL"},{"label":"Open-Label Active Treatment Enrolled from Phase 3","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another \"qualifying\" study of CP-690,550\n\nA sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550","primaryOutcome":{"measure":"Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports","timeFrame":"Includes laboratory test abnormality data for all visits and adverse event data up to 999 days after last dose of study drug","effectByArm":[{"arm":"Initial Period: Tofacitinib 5 Milligram(mg) Twice Daily (BID)","deltaMin":991,"sd":null},{"arm":"Initial Period: Tofacitinib 10 mg BID","deltaMin":2963,"sd":null},{"arm":"Initial Period: All Tofacitinib","deltaMin":3954,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":469,"countries":["United States","Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Chile","China","Colombia","Costa Rica","Croatia","Czechia","Denmark","Dominican Republic","Finland","France","Germany","Greece","Hungary","India","Ireland","Italy","Malaysia","Mexico","New Zealand","Peru","Philippines","Poland","Puerto Rico","Romania","Russia","Slovakia","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["38883150","38854417","37453736","36931693","36601090","36600185","36526796","34973077","34870800","33127856","33057725","32816215","32048083","30953540","30425195","29949132","29435359","29417430","28941219","28143815","27334658","25795907","25398374"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921024&StudyName=Long-Term%20Effectiveness%20And%20Safety%20Of%20CP-690%2C550%20For%20The%20Treatment%20Of%20Rheumatoid%20Arthritis"]},"adverseEventsSummary":{"seriousAny":{"events":346,"n":1123},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Urinary tract infection","Bronchitis","Herpes zoster"]}}